The aim of the current review article is to present an overview of the preclinical and clinical data to date for ulotaront, a novel trace amine-associated receptor 1 (TAAR1) agonist in development for the treatment of schizophrenia, with potential to be one of the first drugs with a non-D2 MOA. Here, TAAR1 is linked to schizophrenia.